Table 2:
Participant characteristics
| Characteristic | N (%) | Characteristic | N (%) | |
|---|---|---|---|---|
| Age | CSER investigator | 20 (43%) | ||
| 20–29 | 4 (7%) | |||
| 30–39 | 18 (33%) | CSER Study Affiliation* | ||
| 40–49 | 10 (19%) | BASIC3 | 7 (13%) | |
| 50–59 | 14 (26%) | ClinSeq | 6 (11%) | |
| 60–69 | 7 (13%) | HudsonAlpha | 4 (7%) | |
| 70+ | 1 (2%) | MedSeq | 7 (13%) | |
| MI-ONCOSEQ | 6 (11%) | |||
| Gender | NCGENES | 8 (15%) | ||
| Male | 25 (46%) | NEXT Medicine | 4 (7%) | |
| Female | 29 (54%) | NextGen | 3 (6%) | |
| PediSeq | 6 (11%) | |||
| Race | Other | 4 (7%) | ||
| White non-hispanic | 43 (80%) | |||
| Asian | 7 (13%) | Rating of genetics training | ||
| Other | 4 (7%) | Not at all sufficient | 2 (4%) | |
| Somewhat insufficient | 5 (9%) | |||
| Neutral | 3 (6%) | |||
| Specialty* | Somewhat sufficient | 15 (28%) | ||
| Genetic counseling | 21 (39%) | More than sufficient | 29 (54%) | |
| Medical genetics | 17 (31%) | |||
| Pediatrics | 14 (26%) | Tests ordered/disclosed within 12 months | ||
| Oncology | 11 (20%) | Genetic test | 50 (93%) | |
| Internal medicine | 6 (11%) | Genomic sequencing | 51 (94%) | |
| Cardiology | 4 (7%) | |||
| Other† | 9 (17%) | Practice setting* | ||
| Hospital | 41 (76%) | |||
| Clinic | 16 (30%) | |||
| Other | 12 (22%) | |||
*
Participants could endorse more than one response option.
†
Open-ended responses included neurology/neurogenetics (4), hematology (2), clinical genetics (1), biochemical genetics (1), and “pediatric, preconception, prenatal and cancer” (1).